phase readout
saveNCT07374614: Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib
RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Peking University Shenzhen Hospital. Phase: . Conditions: Non-Small Cell Lung Cancer, ALK, Iruplinalkib, Lorlatinib, Real-world Study, Observational Study
view source ↗
comments(0)
5-min edit window · permanent after that